Blog
Featured post
Truveta Data leads a new era in cancer research
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta delivers an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and advancing critical cancer research.
How Truveta benchmarks AI model quality for clinical concept extraction
As machine learning models increasingly assist in interpreting patient records, understanding how to properly evaluate these models becomes crucial for ensuring reliable clinical...
Truveta Data analysis shows improved outcomes with Impella support in high-risk heart procedures
A recent analysis using Truveta Data reveals that patients undergoing high-risk, non-emergency heart procedures (percutaneous coronary intervention, or PCI) with support from the...
Evaluating recent trends in early measles vaccinations in Texas
Among children in Texas receiving a first measles vaccine prior to two years of life: In March and April 2025, 20.1% of all first measles vaccines were administered to children...
Cancer innovation needs better data—not just better drugs
Cancer is one of the most heavily funded areas of medical research. And yet, with thousands of therapies in development and billions of dollars spent each year, many foundational...
ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease
Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Karthik Murugiah, MBBS, MHS ⊕Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT Section of...
ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation
Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA,...
ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention
Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA,...
Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta is leading a new era in cancer research, delivering an unprecedented breadth of...
Top 5 takeaways from Truveta Symposium 2025
This week we gathered with leaders across healthcare, public health, and life sciences at the 3rd annual Truveta Symposium. Truveta Symposium uniquely brings together leaders...